PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32816920-4 2021 We evaluated the ability of the cyclin-dependent kinase (CDK) inhibitor dinaciclib to block IFNG-induced IDO1 and CD274 expression in 24 human and mouse cancer cell lines as well as in primary cancer cells from patients with PDAC or ovarian carcinoma. dinaciclib 72-82 indoleamine 2,3-dioxygenase 1 Homo sapiens 105-109